AstraZeneca Plc (AZN)

42.72
0.21 0.49
NYSE : Health Technology
Prev Close 42.51
Open 42.52
Day Low/High 42.50 / 42.74
52 Wk Low/High 32.69 / 42.58
Volume 518.14K
Avg Volume 4.86M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 105.49B
EPS 0.80
P/E Ratio 18.96
Div & Yield 1.37 (3.23%)

Latest News

US FDA Approves Expanded FARXIGA And XIGDUO XR Labels For Use In Patients With Type 2 Diabetes And Moderate Renal Impairment

US FDA Approves Expanded FARXIGA And XIGDUO XR Labels For Use In Patients With Type 2 Diabetes And Moderate Renal Impairment

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a label update for FARXIGA ® (dapagliflozin) and XIGDUO ® XR (dapagliflozin and metformin HCl extended-release) expanding use in patients with type 2 diabetes (T2D)...

BRILINTA's Phase III THEMIS Trial Met Primary Endpoint In Patients With Established Coronary Artery Disease And Type-2 Diabetes

BRILINTA's Phase III THEMIS Trial Met Primary Endpoint In Patients With Established Coronary Artery Disease And Type-2 Diabetes

The Phase III THEMIS trial met its primary endpoint which demonstrated that BRILINTA ® (ticagrelor) tablets, taken in conjunction with aspirin, showed a statistically-significant reduction in major adverse cardiovascular events (MACE, a composite of...

Hot Cancer Detection Stock Still Has Room to Run

Hot Cancer Detection Stock Still Has Room to Run

Guardant's liquid biopsy lets oncologists see all of the genomic information of a patient's tumor with a simple blood test. The alternative is a tissue biopsy which can be expensive and risky.

Wall Street Futures Tumble After Weakest December Retail Sales in a Decade

Wall Street Futures Tumble After Weakest December Retail Sales in a Decade

U.S. equity futures turned sharply red Thursday after data showed the weakest reading for December retail sales in nine years, erasing earlier gains linked to progress in trade talks between Washington and Beijing and data showing a surprise jump in January China export activity.

Tanabe Research Labs Announce FDA Acceptance Of Its IND Application For TR1801-ADC (MT-8633), An ADC Targeting CMet Positive Solid Tumors

Tanabe Research Labs Announce FDA Acceptance Of Its IND Application For TR1801-ADC (MT-8633), An ADC Targeting CMet Positive Solid Tumors

SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Tanabe Research Laboratories U.

Institutional Selling, Europe's Economy, Nvidia Earnings Preview: Market Recon

Institutional Selling, Europe's Economy, Nvidia Earnings Preview: Market Recon

What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?

Wall Street Extends Gains on China Trade Talk Optimism; Dollar Hits 2-Month High

Wall Street Extends Gains on China Trade Talk Optimism; Dollar Hits 2-Month High

Wall Street futures extended gains Thursday with investors using signals of moderate progress in trade talks between Washington and Beijing and data showing a surprise jump in January China export activity to boost the broadest measure of U.S. stocks to a 10% gain for the year.

AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook

AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook

AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing demand for its key cancer treatments.

The New Small Biotechs Heating Up the Medical Cannabis Space

The New Small Biotechs Heating Up the Medical Cannabis Space

These companies are working to plant their flag in a new landscape.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Sosei Heptares To Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2

Sosei Heptares To Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2

TOKYO and LONDON, January 7, 2019 /PRNewswire/ -- Milestone achieved with next generation immuno-oncology candidate AZD4635, a novel adenosine 2A receptor antagonist Sosei Group Corporation ("the Company"; TSE: 4565), announces it has been notified today...

Phase III OLYMPUS And ROCKIES Trials For Roxadustat Met Their Primary Endpoints In Chronic Kidney Disease Patients With Anemia

Phase III OLYMPUS And ROCKIES Trials For Roxadustat Met Their Primary Endpoints In Chronic Kidney Disease Patients With Anemia

AstraZeneca today announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoint for the treatment of patients with anemia in chronic kidney disease (CKD) that are either non-dialysis-dependent (NDD) or...

Pyramid Biosciences Announces Exclusive Global License Of AstraZeneca TRK Program For Dermatology And Inflammatory Diseases

Pyramid Biosciences Announces Exclusive Global License Of AstraZeneca TRK Program For Dermatology And Inflammatory Diseases

- Pyramid Biosciences to exclusively develop AstraZeneca's novel cell surface receptor (TRK) program

New Long-Term Data On CALQUENCE Presented At ASH 2018

New Long-Term Data On CALQUENCE Presented At ASH 2018

AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, have presented new, long-term follow-up results for CALQUENCE ® (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma (MCL) and updated...

AstraZeneca Presents Clinical Research Advances For Blood Cancer Patients At 2018 American Society Of Hematology Annual Meeting

AstraZeneca Presents Clinical Research Advances For Blood Cancer Patients At 2018 American Society Of Hematology Annual Meeting

AstraZeneca, together with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American...

FARXIGA Significantly Reduced Hospitalization For Heart Failure Or CV Death In A Broad Patient Population With Type 2 Diabetes In The Landmark DECLARE-TIMI 58 Trial

FARXIGA Significantly Reduced Hospitalization For Heart Failure Or CV Death In A Broad Patient Population With Type 2 Diabetes In The Landmark DECLARE-TIMI 58 Trial

AstraZeneca today announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA (dapagliflozin).

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial Of FARXIGA In Patients With Type 2 Diabetes To Be Featured At AHA 2018

The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial Of FARXIGA In Patients With Type 2 Diabetes To Be Featured At AHA 2018

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular (CV) outcomes trial (CVOT) DECLARE (Dapagliflozin Effect on Cardiovascular Events)-TIMI 58, the broadest SGLT2...

Stocks to Buy, Stocks to Dump in This Volatile Market

Stocks to Buy, Stocks to Dump in This Volatile Market

Common sense says get more defensive.

AstraZeneca To Present New Data Demonstrating Breadth Of Research Portfolio In Renal Disease At ASN Kidney Week 2018

AstraZeneca To Present New Data Demonstrating Breadth Of Research Portfolio In Renal Disease At ASN Kidney Week 2018

AstraZeneca will present new research spanning the Company's Cardiovascular, Renal and Metabolism (CVRM) therapy area at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in San Diego, US, October 23-28, 2018.

(Graphic: Business Wire)

(Graphic: Business Wire)

AstraZeneca and Merck & Co., Inc.

IMFINZI® (durvalumab) Is The First Immunotherapy To Demonstrate Significant Overall Survival Benefit In Unresectable, Stage III Lung Cancer

IMFINZI® (durvalumab) Is The First Immunotherapy To Demonstrate Significant Overall Survival Benefit In Unresectable, Stage III Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of IMFINZI ® (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on...

AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine In The US For 2018-2019 Flu Season

AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine In The US For 2018-2019 Flu Season

AstraZeneca today announced the first shipment of FLUMIST ® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2018-2019 influenza season.

FARXIGA Achieved A Positive Result In The Phase III DECLARE-TIMI 58 Trial, A Large Cardiovascular Outcomes Trial In 17,000 Patients With Type 2 Diabetes

FARXIGA Achieved A Positive Result In The Phase III DECLARE-TIMI 58 Trial, A Large Cardiovascular Outcomes Trial In 17,000 Patients With Type 2 Diabetes

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for FARXIGA ® (dapagliflozin), the broadest SGLT-2 inhibitor CVOT conducted to date.

FASENRA (benralizumab) Shows Consistent Safety And Sustained Efficacy In Long-Term Phase III BORA Trial In Severe Eosinophilic Asthma

FASENRA (benralizumab) Shows Consistent Safety And Sustained Efficacy In Long-Term Phase III BORA Trial In Severe Eosinophilic Asthma

AstraZeneca today announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of FASENRA™ (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma who had previously completed...

Buy Struggling Progenics and Dynavax Here

Buy Struggling Progenics and Dynavax Here

Both biotech stocks are at or near 52-week lows, but don't deserve to be.

TheStreet Quant Rating: A- (Buy)